stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Shares outstanding
CRISPR Therapeutics AG's shares outstanding at the end of fiscal 2025 was $89.9M, up 6.60% from $84.4M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $96.7M. Over the past ten years it has ranged from $5.0M (fiscal 2015) to $89.9M (fiscal 2025) — the current reading is the highest in ten years. CRISPR Therapeutics AG ranks 156th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $89.9M | 6.60% |
| FY2024 | $84.4M | 6.49% |
| FY2023 | $79.2M | 1.90% |
| FY2022 | $77.7M | (3.29%) |
| FY2021 | $80.4M | 21.90% |
| FY2020 | $66.0M | 15.84% |
| FY2019 | $56.9M | 18.70% |
| FY2018 | $48.0M | 19.74% |
| FY2017 | $40.1M | 226.80% |
| FY2016 | $12.3M | 143.33% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $96.7M | 0.24% |
| Jun 2026 | $96.5M | 0.48% |
| Mar 2026 | $96.1M | 6.81% |
| Dec 2025 | $89.9M | (1.51%) |
| 40 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ERAS Erasca, Inc. compare | $311.3M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | $193.8M |
| COGT Cogent Biosciences, Inc. compare | $171.0M |
| EWTX Edgewise Therapeutics, Inc. compare | $120.9M |
| DFTX Definium Therapeutics, Inc. compare | $110.7M |
| CRSP CRISPR Therapeutics AG | $96.7M |
| TVTX Travere Therapeutics, Inc. compare | $94.6M |
| DNTH Dianthus Therapeutics, Inc. compare | $57.3M |
| MANE Veradermics Incorporated compare | $40.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement